Clinical Trial to Evaluate Safety and Efficiency of Mesenchymal Stem Cell in Patients With Hidradenitis Suppurativa

Inclusion Criteria: * Patients who give informed consent for participation in the clinical trial * Diagnosed 6 months before inclusion * Drainage fistula with a minimum of 1 subcutaneous tract and 1 cutaneous drainage orifice evaluated clinically and by cutaneous ultrasound. The fistula must have active drainage 4 weeks prior to inclusion * Treatment with Adalimumab for at least 12 weeks. * Normal renal function or moderate chronic renal insufficiency with creatinine clearance values greater than 60 ml/min or serum creatinine less than 1.5 times the upper limit. * Normal liver function with total bilirubin values less than 1.5 times the upper limit of normal and transaminases \< 2.5 times the upper limit of normal. * Hemogram and coagulation studies within normal values (Leukocytes ≥ 3000, Neutrophils ≥ 1500, Platelets ≥ 100000, hemoglobin\>10g/dl). * Negative blood pregnancy test for patients of childbearing age * Acceptance by the patient, of childbearing age, to use safe contraceptive methods throughout the study, including six months of follow-up. * Willingness and ability to comply with the visit schedule, treatment plan, clinical tests and all study procedures. and all study procedures. Exclusion Criteria: * Poorly controlled HS requiring additional systemic treatment or change of baseline anti-inflammatory therapy * Abscess or inflammatory collection \> 2 cm adjacent to the fistula to be treated. * Previous surgical treatment on the draining fistula * Known history of alcohol abuse in the 6 months prior to study entry * Active malignancy or patients with a history of a previous malignant tumor. * Presence or recent history of severe, progressive and uncontrolled hepatic, hematologic, gastrointestinal, endocrine, pulmonary, cardiac, neurologic, psychiatric or skin disease * Congenital or acquired immunodeficiencies * Positive serology for HIV, HCV or HBV. * Active COVID-19 infection confirmed by serology and PCR or rapid antigen test * Allergy to any of the components/excipients of the Investigational Product * Major surgery or severe trauma in the previous 6 months * Patients unwilling or unable to comply with study procedures. * Anticipated need for surgery in the anatomical area for a reason other than hidradenitis suppurative * Contraindication to the anesthetic procedure * Systemic immunomodulatory biologic therapy other than Adalimumab, topical or systemic antibiotics for HS, systemic or intralesional corticosteroids, live vaccines, or any experimental treatment or intervention study participation. * Contraindication of nuclear magnetic resonance with contrast. * Women who are pregnant, breastfeeding, or of childbearing age who are not using an effective contraceptive method. * Patients who are currently participating or have completed participation in a clinical trial in a period of less than 3 months or who have participated in an Advanced Therapies clinical trial at any previous time and have been assigned to an experimental group.